Phase Forward Introduces New Version of Phase Forward™ Clinical Development Center
04 Mayo 2010 - 8:00AM
Business Wire
Phase Forward (NASDAQ: PFWD), a leading provider of data
management solutions for clinical trials and drug safety, today
announced the latest version of the Phase Forward™ Clinical
Development Center (CDC), a centralized solution for integrating,
managing and analyzing clinical information. This new release
focuses on streamlining the preparation of clinical trial data for
analysis by providing a flexible and effective workflow to track,
manage and reconcile data discrepancies that can be found within
different data sources.
The release also offers “out-of-the-box” integration with the
Phase Forward InForm™ global trial management (GTM) electronic data
capture (EDC) solution. The integration automates study set-up and
delivery of InForm data to the CDC – significantly reducing data
handling time and effort. The integration also provides data
managers with direct links back to InForm, enabling them to
simplify the process of reviewing study source data or issuing
queries.
“Our customers are looking for a centralized solution to
efficiently process the increasing amounts of data collected within
clinical trials,” said Martin Young, Phase Forward Senior Vice
President, Integration and Product Strategy. “This new version of
Phase Forward CDC delivers a means to more expeditiously and
effectively manage this process. The enhanced integration with
InForm extends this benefit, giving our customers a way to leverage
their existing investments by providing even greater levels of
automation and efficiency.”
Demands on data managers and biostatisticians to prepare and
“clean” data for analysis continue to grow as today’s increasingly
complex and distributed clinical trials generate unprecedented
amounts of electronic information, including patient and lab data,
images, statistical programs, plans and other supporting documents.
The Phase Forward CDC application helps data managers more
efficiently load, transform and reconcile data – streamlining
workflows and improving the readiness of new datasets for interim
analysis. The combination of this new functionality with the
existing open systems approach, providing the ability to integrate
data from multiple systems providers, and the powerful automated
traceability and control capabilities of the CDC enables sponsors
to better manage, track and ensure analysis is current and
accurate.
About Phase Forward
Phase Forward is a leading provider of integrated data
management solutions for clinical trials and drug safety. Phase
Forward’s products and services have been utilized in over 10,000
clinical trials involving more than 1,000,000 clinical trial study
participants at over 300 organizations and regulatory agencies
worldwide including: AstraZeneca, Boston Scientific, Dana-Farber
Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration,
GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono,
Novartis, Novo Nordisk, PAREXEL International, Procter &
Gamble, Quintiles, sanofi-aventis, Schering-Plough Research
Institute, Servier, SGS, Tibotec and the U.K. Medicines and
Healthcare Products Regulatory Agency. Additional information about
Phase Forward is available at www.phaseforward.com.
Cautionary Statement
Certain statements made in this press release that are not based
on historical information are forward-looking statements which are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. This press release
contains express or implied forward-looking statements relating to,
among other things, the performance and acceptance of Phase
Forward’s products, features of Phase Forward products that are not
believed to be available in competing products, and the benefits to
customers from the use of such products. These statements are
neither promises nor guarantees, but are subject to a variety of
risks and uncertainties, many of which are beyond Phase Forward's
control, which could cause actual results to differ materially from
those contemplated in these forward-looking statements. In
particular, the risks and uncertainties include, among other
things, Phase Forward's inability to convince current and potential
customers to order its products, the failure of customers to
realize benefits from the use of these products, changes in
industry standards, changes in the manner in which Phase Forward
customers conduct business, and changes in or introduction of
competitive products. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Phase Forward
undertakes no obligation to update or revise the information
contained in this press release, whether as a result of new
information, future events or circumstances or otherwise. For
additional disclosure regarding these and other risks faced by
Phase Forward, see the disclosure contained in Phase Forward's
public filings with the Securities and Exchange Commission
including, without limitation, its most recent Annual Report on
Form 10-K.
Phase Forward (NASDAQ:PFWD)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Phase Forward (NASDAQ:PFWD)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024